Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation

Oncotarget

Volumn 7, Issue 28, 2016, Pages 43109-43123

  Peres, Rafael ^a   Furuya, Hideki ^a   Pagano, Ian ^a   Shimizu, Yoshiko ^a,b   Hokutan, Kanani ^a,b   Rosser, Charles J ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Angiogenin; Bladder cancer; DNMT3b; MMP2

Indexed keywords

ANGIOGENIN; DNA METHYLTRANSFERASE 3B; GELATINASE A; MESSENGER RNA; ONCOPROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; MMP2 PROTEIN, HUMAN; PANCREATIC RIBONUCLEASE; SMALL INTERFERING RNA; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; CARCINOGENESIS; CELL MIGRATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC MANIPULATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MMP2 GENE; MODULATION; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; BLADDER TUMOR; CELL MOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RNA INTERFERENCE; SECRETION (PROCESS); TUMOR CELL LINE;

BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASES; DNA METHYLATION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; RIBONUCLEASE, PANCREATIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84978730223     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10097     Document Type: Article

References (38)

1. Sharma S, De Carvalho DD, Jeong S, Jones PA and Liang G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet. 2011; 7:e1001286
2. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16:6-21
3. Jones PA and Baylin SB. The epigenomics of cancer. Cell. 2007; 128:683-692
4. Kim GD, Ni J, Kelesoglu N, Roberts RJ and Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 2002; 21:4183-4195
5. Nakagawa T, Kanai Y, Saito Y, Kitamura T, Kakizoe T and Hirohashi S. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. J Urol. 2003; 170:2463-2466
6. Okano M, Bell DW, Haber DA and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999; 99:247-257
7. Robertson KD, Uzvolgyi E, Liang GN, Talmadge C, Sumegi J, Gonzales FA and Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999; 27:2291-2298
8. Miyake M, Goodison S, Lawton A, Gomes-Giacoia E and Rosser CJ. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene. 2015; 34:890-901
9. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF and Vallee BL. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985; 24:5480-5486
10. Hisai H, Kato J, Kobune M, Murakami T, Miyanishi K, Takahashi M, Yoshizaki N, Takimoto R, Terui T and Niitsu Y. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res. 2003; 9:4852-4859
11. Barcena C, Stefanovic M, Tutusaus A, Martinez-Nieto GA, Martinez L, Garcia-Ruiz C, de Mingo A, Caballeria J, Fernandez-Checa JC, Mari M and Morales A. Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer. Scientific reports. 2015; 5:7916
12. Etoh T, Shibuta K, Barnard GF, Kitano S and Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res. 2000; 6:3545-3551
13. Ramcharan SK, Lip GY, Stonelake PS and Blann AD. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer. Eur J Clin Invest. 2013; 43:801-808
14. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA and Cheng L. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res. 2005; 11:8358-8363
15. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer. 1999; 86:316-324
16. Tsuji T, Sun YQ, Kishimoto K, Olson KA, Liu SM, Hirukawa S and Hu GF. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res. 2005; 65:1352-1360
17. Irwin JC, Kirk D, Gwatkin RBL, Navre M, Cannon P and Giudice LC. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase-Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest. 1996; 97:438-447
18. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C and Clark SJ. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer cell. 2013; 23:9-22
19. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jr., Jahromi MS, Xekouki P, Szarek E, Walker RL, Lasota J, Raffeld M, Klotzle B, Wang Z, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer discovery. 2013; 3:648-657
20. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH and Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012; 18:1323-1333
21. Chakraborti S, Mandal M, Das S, Mandal A and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003; 253:269-285
22. Yan C and Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007; 211:19-26
23. Chou J, Shahi P and Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013; 12:3262-3271
24. Campos K, Gomes CC, Farias LC, Silva RM, Letra A and Gomez RS. DNA Methylation of MMP9 Is Associated with High Levels of MMP-9 Messenger RNA in Periapical Inflammatory Lesions. J Endod. 2016; 42:127-130
25. Szyf M and Detich N. Regulation of the DNA methylation machinery and its role in cellular transformation. Prog Nucleic Acid Res Mol Biol. 2001; 69:47-79
26. Bannister AJ and Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011; 21:381-395
27. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3:415-428
28. Esteller M, Corn PG, Baylin SB and Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61:3225-3229
29. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000; 249:135-164
30. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of highrisk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18:956-962
31. Yoder JA, Soman NS, Verdine GL and Bestor TH. DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. Journal of Molecular Biology. 1997; 270:385-395
32. Rhee I, Bachman KE, Park BH, Jair KW, Yen RWC, Schuebel KE, Cui HM, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB and Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002; 416:552-556
33. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF and Dinney CPN. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urology. 2004; 171:570-574
34. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D and Loening SA. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001; 57:675-679
35. Sier CFM, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, Blasi F and Hanemaaijer R. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clinical Cancer Research. 2000; 6:2333-2340
36. Weinstein IB and Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006; 3:448-457
37. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S and Rosser CJ. Influencing factors on the NMP-22 urine assay: an experimental model. Bmc Urology. 2012; 12
38. Tamashiro PM, Furuya H, Shimizu Y and Kawamori T. Sphingosine kinase 1 mediates head & neck squamous cell carcinoma invasion through sphingosine 1-phosphate receptor 1. Cancer cell international. 2014; 14:76